- $260.14m
- $169.99m
- 40
- 18
- 23
- 16
Annual balance sheet for Candel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 35.1 | 82.6 | 70.1 | 35.4 | 103 |
| Prepaid Expenses | |||||
| Total Current Assets | 35.1 | 84.9 | 71.9 | 36.8 | 104 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.79 | 3.84 | 5.48 | 4.02 | 2.73 |
| Other Long Term Assets | |||||
| Total Assets | 38.3 | 89.2 | 77.7 | 41.2 | 107 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.71 | 5.36 | 5.62 | 14.2 | 37.5 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.8 | 25.1 | 30 | 28.5 | 40.5 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 25.5 | 64.1 | 47.7 | 12.7 | 66.3 |
| Total Liabilities & Shareholders' Equity | 38.3 | 89.2 | 77.7 | 41.2 | 107 |
| Total Common Shares Outstanding |